Most treatment-emergent adverse events were mild to moderate in adult ITP patients receiving 4 or 7 mg/kg of rozanolixizumab subcutaneously.
Cumulative duration of platelet response ≥ 50 x 109/L without rescue therapy was superior with avatrombopag vs placebo.
At full cost, rivaroxaban increases total healthcare costs but lowers clinical event costs vs aspirin when given as extended anticoagulant therapy for VTE.
In this post hoc analysis, platelet counts ≥ 50 x 109/L were reached without rescue therapy in 84% of patients with persistent ITP vs 88% with chronic ITP.
In this subgroup analysis of a phase II study, high-dose crizanlizumab delayed sickle cell–related pain crises across all defined subgroups of patients with sickle cell disease.
Compared with dalteparin, rivaroxaban was associated with a lower incidence of VTE recurrence within 6 months but a higher incidence of clinically relevant bleeding events.
Initiation of eltrombopag reduced mean number of transfusions and healthcare resource utilization rates vs before eltrombopag administration.
Emicizumab prevented or reduced bleeding episodes requiring treatment and was well tolerated by this pediatric population.
Preliminary analysis finds that pharmacokinetic parameters of SC emicizumab Q4W were promising and consistent with previous observations.
In this Expert Analysis of key data from the Hematology 2017 annual meeting, Julie Kanter, MD; Gary Lyman, MD, MPH, FASCO, FRCP (Edin); Keith R. McCrae, MD; and Guy A. Young, MD, discuss the clinical applicability of new findings in nonmalignant hematologic disorders presented at the conference, including sickle cell disease, immune thrombocytopenia, hemophilia A, venous thromboembolism, and aplastic anemia.
Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.